Literature DB >> 8381846

Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions.

G Bazzoni1, A Beltrán Nuñez, G Mascellani, P Bianchini, E Dejana, A Del Maschio.   

Abstract

The in vitro effect of unfractionated heparin and dermatan sulfate, as well as oligo-heparin and oligo-dermatan sulfate, on human PMN function was investigated. Superoxide anion generation in fMLP-stimulated PMN was dose-dependently reduced by heparin and oligo-heparin, while DS and oligo-DS lacked inhibitory activity. FMLP-stimulated PMN adhesion to endothelial cells was reduced to a similar extent by both heparin and oligo-heparin, but not by DS and oligo-DS. On the other hand, none of the compounds affected the adhesion of unstimulated PMN to either IL-1- or PMA-activated endothelial cells. Heparin and oligo-heparin also inhibited the homotypic aggregation of fMLP-stimulated PMN. As reported, coincubation of platelets with fMLP-stimulated PMN resulted in platelet activation, a process mainly mediated by the PMN-derived serine protease cathepsin G. Both heparin and DS, as well as their oligo-derivatives, reduced platelet activation induced by either fMLP-stimulated PMN or purified leukocytic cathepsin G. Finally, besides cathepsin G, also the activity of beta-glucuronidase and lysozyme released by stimulated PMN were reduced by heparin, oligo-heparin and DS. These data support the hypothesis that heparin and other GAGs may exert an antiinflammatory role.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381846

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

1.  The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin.

Authors:  Helen Jones; William Paul; Clive P Page
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 3.  Bidirectional modulation of platelet and polymorphonuclear leukocyte activities.

Authors:  A Del Maschio; E Dejana; G Bazzoni
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

4.  Interaction of heparin with synthetic peptides corresponding to the C-terminal domain of intestinal mucins.

Authors:  G Xu; G G Forstner; J F Forstner
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

5.  The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro.

Authors:  R Lever; J R Hoult; C P Page
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

6.  Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism.

Authors:  A Salas; M Sans; A Soriano; J C Reverter; D C Anderson; J M Piqué; J Panés
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

7.  The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.

Authors:  A Smailbegovic; R Lever; C P Page
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin.

Authors:  M M Teixeira; P G Hellewell
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

9.  Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro.

Authors:  Rachel A Brown; Rebecca Lever; Neil A Jones; Clive P Page
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

10.  Size-fractionated heparins have differential effects on human neutrophil function in vitro.

Authors:  R Lever; W T Lo; M Faraidoun; V Amin; R A Brown; J Gallagher; C P Page
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.